As a Diabetologist with many years of experience, I have observed that managing type 2 diabetes often involves not only addressing blood sugar levels but also associated factors like obesity.
We must understand that Diabetes is more than just blood sugar. It is a complex metabolic disorder that impacts multiple body systems. Treatments focused primarily on glucose control, often overlooking the crucial aspects of weight management and cardiovascular health.
Understanding the Role of SGLT-2 Inhibitors
The kidney is our body’s filtering system. When the blood passes through the kidneys, all the glucose is reabsorbed back into the bloodstream. This process is inhibited by SGLT-2 inhibitors.
They block the SGLT2 protein in kidney tubules and prevent glucose reabsorption. This causes excess glucose to be excreted through urine, and the blood glucose levels are reduced independently of insulin.
Unlike other diabetic medications, SGLT-2 inhibitors offer a multi-dimensional approach:
- Independent of pancreatic insulin production
- Works effectively in various metabolic states
- Minimal hypoglycaemia risk
- Potential cardiovascular and renal protective effects.
Common SGLT-2 inhibitors in clinical practice are
- Empagliflozin
- Dapagliflozin
- Canagliflozin
The medication interacts with many metabolic pathways, and it reduces insulin secretion, decreases fat storage, improves metabolic flexibility, and enhances fat storage.
The Connection Between Weight Loss and SGLT-2 Inhibitors.
The weight loss associated with SGLT2 inhibitors primarily results from the loss of calories due to increased urinary glucose excretion. This calorie deficit leads to a reduction in body weight. Additionally, the excretion of glucose may promote the breakdown of fat stores, which contributes to weight loss.
On average, one may experience a reduction of approximately 2 to 4 kg. This effect is observed when used as monotherapy and in combination with other anti-diabetic medications.
There are clinical trials that show SGLT-2 inhibitors lead to weight loss in people with type 2 diabetes. A 2.73 kg weight loss was seen in people compared to those who used other anti-diabetic agents. When Dapagliflozin was administered along with Metformin, a reduction of approximately 3 kg in weight loss.
The weight loss-reducing effect of SGLT-2 inhibitors tends to plateau after about one year of treatment. This plateau may be partly due to compensatory mechanisms, such as an increase in appetite and calorie intake, which can offset further weight loss.
Although it is beneficial in losing weight, it does have some drawbacks
- It increases urinary tract infection risk
- Potential genitourinary side effects
- Individual metabolic variability
- Not suitable for all patient populations.
It is important to note that the degree of weight loss with SGLT-2 inhibitors can vary among individuals. Factors such as baseline HbA1c levels influence outcomes, and with higher HbA1c, individuals may experience higher weight loss. Mechanisms like increased appetite may reduce weight loss over time.
Incorporating SGLT-2 inhibitors into the treatment regimen for Type 2 Diabetes offers the dual benefit of improving blood glucose control and promoting weight loss. While the weight reduction is significant, it can contribute to the overall management of diabetes and associated comorbidities.
Remember, treatment plans should be personalised. Always talk to your healthcare provider before starting on any medication.
